Stockscreener 앱 받기
4.15
3.49%
0.14
시간 외 거래:
4.15
전일 마감가:
$4.01
열려 있는:
$4.05
하루 거래량:
2.41M
Relative Volume:
0.59
시가총액:
$431.11M
수익:
-
순이익/손실:
$-165.67M
주가수익비율:
-1.88
EPS:
-2.2075
순현금흐름:
$-113.29M
1주 성능:
-4.38%
1개월 성능:
-17.82%
6개월 성능:
+19.60%
1년 성능:
+97.62%
1일 변동 폭
$4.00
$4.28
1주일 범위
$3.88
$4.37
52주 변동 폭
$1.73
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.15 | 416.57M | 0 | -165.67M | -113.29M | -2.2075 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path - MyChesCo
MSN Money - MSN
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR) - The Globe and Mail
Larimar Therapeutics, Inc. $LRMR Shares Acquired by AIGH Capital Management LLC - MarketBeat
LRMR Forecast, Price Target & Analyst Ratings | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Millennium Management (LRMR) reports 3.5% ownership; 3,625,278 shares - Stock Titan
Larimar Therapeutics Publishes Cross-Species Findings - GlobeNewswire
Larimar Therapeutics stock dips after pricing $100M share offering - MSN
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Larimar Therapeutics launches proposed $75 million public offering - MSN
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Larimar Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Friedreich's Ataxia Pipeline Enters a Transformative Era with - openPR.com
Friedreich’s Ataxia Pipeline Enters a Transformative Era with 20+ Therapies and Strong Clinical Momentum from Larimar Therapeutics, Minoryx Therapeutics, and Design Therapeutics | DelveInsight - Barchart
Larimar Therapeutics (LRMR) Stock: Pricing Evaluation | Q4 2025: Profit DisappointsNet Margin - Cổng thông tin điện tử tỉnh Tây Ninh
Larimar Therapeutics (LRMR) to Release Earnings on Wednesday - MarketBeat
Larimar Therapeutics (NASDAQ: LRMR) targets director votes and higher authorized share count - Stock Titan
[ARS] Larimar Therapeutics, Inc. SEC Filing - Stock Titan
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics (NASDAQ: LRMR) asks shareholders to double authorized shares to 215M - Stock Titan
Analysts Set Larimar Therapeutics Price Target at $16.50 - National Today
Investment Review: Is Larimar Therapeutics Inc currently under institutional pressure2026 Breakouts & Breakdowns & Stepwise Swing Trade Plans - baoquankhu1.vn
Can Larimar Therapeutics (LRMR) Stock Maintain Growth | Price at $5.14, Up 0.98%Social Buzz - Cổng thông tin điện tử tỉnh Tây Ninh
Pullback Watch: Is Larimar Therapeutics Inc forming a double bottom2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Pharma News: Is Larimar Therapeutics Inc impacted by rising ratesWeekly Stock Summary & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Will Larimar Therapeutics (LRMR) Stock Rise in 2026 | Price at $4.79, Down 0.10%Hot Community Stocks - Xã Thanh Hà
Larimar surges on FDA breakthrough status for lead asset - MSN
LRMR Technical Analysis & Stock Price Forecast - Intellectia AI
LRMR PE Ratio & Valuation, Is LRMR Overvalued - Intellectia AI
Biotech Larimar heads to Miami for back-to-back investor meetings in March - Stock Titan
Q1 Earnings Estimate for LRMR Issued By Lifesci Capital - MarketBeat
LRMR SEC FilingsLarimar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Larimar reports results, advances Nomlabofusp toward FDA filing - MSN
Earnings Recap: Does Larimar Therapeutics Inc have consistent dividend growthMarket Growth Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Buyback Watch: Is Larimar Therapeutics Incs growth already priced in2026 Weekly Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Larimar Therapeutics Inc impacted by rising ratesProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Wedbush raises its price target on Larimar Therapeutics (LRMR) to $13 - MSN
Profit Recap: Will Larimar Therapeutics Inc stock hit new highs in YEAR2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 - Insider Monkey
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):